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Abstract 
This review will focus on the interaction of herpes simplex virus type 1 (HSV-1) and its 
causative role in pathogenesis of Alzheimer’s disease (AD) noting specifically, the 
epidemiological relevance of addressing this problem, as well as the molecular pathways 
associated. HSV-1 reactivation tends to be one of the primary causative events that is responsible 
for many of the pathologies associated with AD, such as: amyloid beta (Aβ) accumulation 
caused by malfunctioning cleavage of amyloid precursor protein (APP) as well as tau 
hyperphosphorylation. HSV-1 reactivation is a primary causative event in downstream 
dysfunction and is also shown to be directed by the c-Jun N-terminal kinase (JNK) stress 
pathway; however, the glycogen synthase kinase type-3 (GSK-3) pathway is most important for 
Aβ accumulation and is also associated with tau hyperphosphorylation: the two proteins 
responsible for AD. The purpose of discussing these molecular pathways associated with the 
connection between HSV-1 and AD is to prove that proactive treatment is a necessity, while also 
advocating for a more detailed understanding of the causative affects of HSV-1 on AD. This 
review is important to increase awareness of the association between this highly prevalent virus 
and an extremely debilitating disease, with the goal of increased understanding and treatment for 
both HSV-1 and Alzheimer’s disease.  
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Introduction 
 Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder characterized 
by the decline of cognitive functions such as: memory, reasoning, language, etc. (Selkoe, 2011). 
This disease’s etiology is rooted in normally soluble proteins: amyloid β-protein (Aβ) and tau 
(Selkoe, 2011). Aβ plaques are produced in nets that surround neurons and have become a 
hallmark of AD diagnosis (Selkoe, 2011).  AD alone is the “sixth leading cause of death in the 
United States” (McQuillan & Paulose-Ram, 2018) and in 2010, out of all states and the District 
of Columbia, the CDC found that 31 of those states showed “death rates from Alzheimer’s 
disease that were above the national rate” (McQuillan & Paulose-Ram, 2018). Though there are 
numerous risk factors associated with AD, infectious agents may be key players in understanding 
AD pathogenesis. Specifically, epidemiological and experimental evidence is beginning to 
demonstrate a link between Herpes Simplex Virus type 1 (HSV-1) reactivation and AD 
pathogenesis (Lövheim, Gilthorpe, Adolfsson, Nilsson, & Elgh, 2015). HSV-1 was found to have 
a prevalence of 47.8% in 2015 and the prevalence was found to increase with age (Tejada-Vera, 
2013). HSV-1 reactivation is the primary event that induces cellular cascades, that eventually 
lead to Aβ accumulation (Piacentini et al., 2015). C-Jun N-terminal kinase (JNK) have been 
found to be a critical component in HSV-1 reactivation, as well as histone demethylase activity 
(Cliffe et al., 2015). The link between HSV-1 and AD is being explored through mechanisms 
related to the production of Aβ protein aggregates, looking specifically at how these aggregates 
are formed, namely through amyloid precursor protein (APP) cleavage pathways (Chang et al., 
2006; Kimberly, 2005; Kimura, Hata, & Suzuki, 2016; Piacentini et al., 2015). It is now known 
that phosphorylation of threonine residue at position 668 (Thr668) is a critical step in the 
downstream production of Aβ (Chang et al., 2006; Piacentini et al., 2015), and is then dependent 
upon glycogen synthase kinase (GSK)-3, JNK, and Cyclin-dependent kinase 5; though there is 
some debate surrounding which pathway is most important, some recent experiments report 
compelling evidence for the GSK-3 mediation of APP phosphorylation, and the subsequent Aβ 
production (Piacentini et al., 2015). This literature suggests that HSV-1 reactivation pathways 
could be playing a critical role in Aβ production, and subsequently, the development of AD; 
however, there is still debate surrounding what cellular pathways lead to the subsequent 
accumulation of Aβ, as well as, what function this performs for the cell, be it protective, or 
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purely detrimental. The purpose of this paper is to review the current literature available on 
cellular pathways related specifically to Aβ production, while aiming to understand what this 
means for neural function and how this relates to Alzheimer’s disease.  
 
Alzheimer’s Disease 
Epidemiology of Alzheimer’s Disease 
 Posing a significant threat to the aging population across the globe, treatment and 
understanding of AD is still lacking. Newfound focus has been placed on the amyloid 
hypothesis, showing that amyloid β plaques play a critical role in inducing AD pathology. One 
important set of structures observed in the brain of those with Alzheimer’s include, “senile 
plaques, and neurofibrillary tangles (NFTs)”. Senile plaques are extracellular protein aggregates 
composed of Aβ, a protein formed via the cleavage of a neural cell integral membrane protein, 
amyloid precursor protein (APP) (Harris & Harris, 2018). NFT’s are intracellular deposits of 
“abnormally hyperphosphorylated tau proteins” (Harris & Harris, 2018). Though some debate 
surrounds which protein (amyloid or tau) is more important in understanding AD pathogenesis, 
Lewis et al., 2001 demonstrated through analysis of transgenic mice overexpressing both mutant 
human APP, and tau protein, that said mice undergo an increased genesis of tau-positive tangles 
with Aβ plaques being unaltered in both structure, and number (Lewis et al., 2001). Compared to 
mice that overexpressed tau protein alone, this finding demonstrates that altered APP processing 
occurs before tau alterations occur downstream in the AD pathogenic cascade. Other studies 
have supported this previous finding, concluding that AB toxicity was dependent on tau through 
the examination of mice hippocampal cultures. This information suggests that tau proteins do 
play a significant role in AD pathology; however, tau proteins are a downstream byproduct that 
is produced due to alterations in Aβ anabolism or clearance pathways.  
 
Amyloid Beta’s Importance in Alzheimer’s Disease 
 Though it is known that Aβ plays a significant role in AD, it also important to note the 
vitality of Aβ in its non-pathogenic form, as this can provide possibly explanations as to how 
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HSV-1 is disrupting these functions. In normal brains, amyloid beta peptides are found at low 
levels, and may play a critical role in synaptogenesis, antioxidant activity, calcium homeostasis 
and neurogenesis (Cárdenas-Aguayo et al., 2014). While, in AD brains, or brains rich amyloid 
fibril plaques, quantifable neuron loss is recorded within mice hippocampus at ages 14-18 
months (Selkoe, 2011). AD, though complex, is highly dependent upon Aβ accumulation in the 
form of senile plaques, and the subsequent NFTs development caused by hyperphosphorylated 
tau.  
 
Herpes Simplex Virus Type-1 
HSV-1: Structure and Prevalence 
 HSV-1, a high prevalent virus, affects about 3.7 billion (67% of the adult population) 
people globally and is a neurotropic pathogen that has an increased prevalence with age (World 
Health Organization, 2017). The virus primarily infects epithelial cells of the oral and nasal 
mucosa. During lytic replication viral particles may reach sensory neurons, and then via axonal 
transport travel to the trigeminal ganglion. From the trigeminal ganglion the virus may travel via 
axonal transport thus reaching the central nervous system (CNS) (Piacentini et al., 2014). Post 
infection the virus enters a lysogenic lifecycle, lying dormant in the host sensory ganglia 
allowing for a life-long infection: bypassing and evading the host immune system (Cliffe & 
Wilson, 2017). When reactivation occurs and the virus enters a productive lifecycle, lytic lesions 
arise termed: herpes labialis or cold sores (Piacentini et al., 2014). The viral reactivation which 
induces lesions, occur in episodes. The virus will then return to to a dormant (lysogenic) 
lifecycle until the next episode. This shows that HSV-1 not only has access to the brain but has a 
unique lifecycle that forces lytic genes to rely on cellular machinery and activities.  
 
JNK Pathway is Essential for HSV-1 Reactivation 
 An important pathway to HSV-1 reactivation is the JNK stress pathway. This pathway is 
dependent upon the inhibition of phosphoinositide 3-kinase (PI3K) signaling (Cliffe & Wilson, 
2017). The reason PI3K must be inhibited to initiate lytic mRNA synthesis is because the cell 
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lacks viral proteins, and thus the reactivation of lytic genes must rely on cellular machinery and 
activities. In neurons JNK, a common stress-response pathway, is also involved in dendritic 
arborization and synaptic plasticity (Coffey, 2014). Considering that both functions are affected 
by AD pathology, this poses a possible mechanistic link between HSV-1 and AD pathology. 
JNK is also essential for HSV gene expression during reactivation and induces a methyl/phospho 
switch on histone H3S10, activating viral lytic promoters. Due to this unique mechanism of 
histone modification, lytic gene expression is able to occur, all while repressive histone 
modifications (lysine residues) remain (Cliffe et al., 2015). This mechanism shows how 
“episodes” of transcription occur: a key characteristic of HSV-1. This shows that the JNK 
pathway is one major reactivation cascade that can allow for lytic gene expression to occur via 
activation of a normally dormant heterochromatic set of DNA; however, JNK does not appear to 
be a critical step involved in the accumulation of Aβ.  
 
GSK-3 Mediation of Both Amyloid Beta Accumulation, and Tau Hyperphosphorylation 
 Piacentini et al. (2015) reports that GSK-3 is the primary kinase involved in 
phosphorylation of APP at Thr668 in rat cortical neurons in vitro. This phosphorylation of APP 
through calcium-activated GSK-3 is an essential step in the Aβ accumulation process. APP is 
both a substrate for JNK, and GSK-3, though there is no significant phosphorylation of APP by 
JNK (Piacentini et al., 2015). This suggests that JNK may only play a role in the reactivation 
process, and not the subsequent accumulation of Aβ. It has been found that HSV-1 infected cells 
hyperphosphorylated tau protein at a significantly higher rate (by a factor of four), and that HSV-
1 upregulates GSK-3β, which is an enzyme also involved in phosphorylation of tau proteins: not 
only APP (Harris & Harris, 2018). GSK-3 could be a shared pathway between both Aβ 
accumulation, and tau hyperphosphorylation, thus serving as a connection between the two 
proteins that are both key components of neural dysfunction associated with AD. Both amyloid 
proteins are manipulated by GSK-3, as well as tau proteins, showing a direct mechanistic link 
between HSV-1 and AD, a disease that is dependent upon both Aβ and tau.  
 
 
The Association Between Herpes Simplex Virus Type 1 Reactivation and Alzheimer’s Disease 
 6  
 
Synaptic Dysfunction 
Presynaptic Protein Downregulation Connected with GSK-3 and HSV-1 
 Neural dysfunction and reduced synaptic activity can be measured by examining two pre-
synaptic proteins. These two synaptic proteins are known as Synapsin-1 and synaptophysin with 
both being reported in decreased levels of AD brains (Harris & Harris, 2018). Importantly, HSV-
1 infected cells also produce marked decreases in both proteins as well. To understand how this 
occurs, the GSK-3 pathway was studied in relation to both presynaptic proteins. Although, GSK-
3 is an important molecular pathway in understanding how amyloid proteins accumulate, there is 
no evidence showing that GSK-3 has a direct involvement in neural dysfunction; rather, an 
indirect involvement. It has been reported that, even when GSK-3 is inhibited, synapsin-1 and 
synaptophysin levels do not change; rather, when amyloid precursor proteins are present, both of 
the presynaptic proteins are both reduced (Piacentini et al., 2015). This means that while GSK-3 
is directly involved in the production of APP, it is not directly responsible for reducing synapsin-
1 and synaptophysin levels; rather, GSK-3 is an upstream modulator of APP, the ladder 
producing a decrease in synapsin-1 and synaptophysin. 
 
HSV-1 Affects CREB Via GSK-3 Pathway 
 GSK-3 activation and Aβ accumulation are both important components in understanding 
the disease pathology of Alzheimer’s. GSK-3, playing a major role in both Aβ and tau protein 
accumulation, is also important in understanding how this HSV-1 can induce synaptic 
dysfunction. GSK-3 has been found to be an upstream regulator of the cyclic AMP-response 
element-binding protein (CREB). CREB is a major indicator of synaptic function and is a target 
of Aβ (Harris & Harris, 2018). Importantly, GSK-3 has been found to induce upregulation of 
CREB phosphorylated at ser 129 (CREBser 129). CREBser 129 is the inhibitory version of the 
transcription factor: CREB (Piacentini et al., 2015). This indicates that HSV-1, an up-regulatory 
agent of the GSK-3 pathway, indirectly increases the levels of CREBser 129.  It is unclear what this 
means for other downstream events and needs further research to uncover what explicitly this 
means for the accumulation of Aβ; though, it is clear that the transcription factor (CREB) is 
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essential in understanding exactly how HSV-1 infection can lead to neural dysfunction: a 
hallmark of AD.  
Antiviral Agents as Proactive Treatment for Alzheimer’s Disease 
 As demonstrated, there is a significant pathological overlap between Alzheimer’s disease 
and herpes simplex virus type-1 (HSV-1) viral reactivation mechanisms, both involved in neural 
degradation and decreased synaptic potential. Primarily, this dysfunction is a result of the GSK-3 
pathway, a kinase that is activated by the large influx of calcium induced by viral reactivation. 
Not only is there a molecular overlap in pathology between this virus and AD, some studies have 
explored HSV-1 as an additive agent. In a large matched cohort study performed in Taiwan with 
information gathered from their National Health Insurance Program, it was found that in 
comparison to non-HSV-infected subjects, those with HSV infections had an increased risk of 
any type of dementia, even after controlling for individuals that were diagnosed with dementia 
within the first 5 years (Tzeng et al. 2018). This research supports the notion that there is a more 
direct link between not only HSV-1, but HSV-2 as well. Considering that Herpes Simplex Virus 
(Types 1 and 2) is a prevalent global virus and has a direct link with multiple forms of dementia, 
treatment and development of new treatments should be pursued. Tzeng et al. 2018 reported that 
subjects that were treated for herpes infections with anti-herpetic medications, had approximal 3 
times reduced risk of Alzheimer’s disease, as well as overall dementia. In short: their findings 
show that if a patient is treated for a herpes simplex infection, then their risk for dementia is 
similar to that of someone who does not have the virus at all. Medications such as Acyclovir, 
Valaciclovir, Famciclovir, Ganciclovir, and Valganciclovir are all examples of anti-herpetic 
medications that can be used for the treatment of herpes simplex type virus (Tzeng et al., 2018). 
It is important to note that while this research is useful for providing a possible link between AD 
and HSV, there are confounding variables that the researchers could not control for, as well as all 
the information for dementia was gathered via insurance claims. Despite these limitations, this 
study provides a strong framework for further clinical trials utilizing anti-herpetic medications in 
the proactive treatment of AD.  
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Conclusion  
 The neurodegenerative disease: Alzheimer’s disease, is a major threat for the aging 
population, both in the United States, and across the globe. Alzheimer’s disease is characterized 
by the accumulation of amyloid beta plaques, and tau hyperphosphorylation aggregates, that both 
disrupt neural function. Importantly, the herpes simplex virus type 1 (HSV-1) is known to 
directly modify the production of amyloid beta proteins and has an indirect influence on tau 
hyperphosphorylation through the glycogen synthase type 3 pathway (GSK-3). HSV-1 is even 
more prevalent than Alzheimer’s disease with a dramatic prevalence rate across the globe. 
Herpes simplex virus type 1 normally influences molecular pathways during its reactivation, or 
the transition from a lysogenic (latent) lifecycle, to a lytic (active) lifecycle. This process has 
been shown to be mediated by the c-Jun N terminal kinase stress response pathway (JNK); 
however, the JNK pathway is not directly responsible for abnormal protein accumulation. In this 
paper I have explored each of these molecular pathways, and how they further the argument that 
HSV-1 is a causative agent in AD pathogenesis, thus showing that the need for proactive 
treatment of AD is necessary, in conjunction with increased research into the link between this 
virus and other types of dementia, including AD.  
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